Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.4 USD | +3.85% | -12.20% | -22.86% |
May. 17 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
May. 14 | KALA BIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.86% | 14.65M | |
+51.99% | 803B | |
-5.72% | 351B | |
+18.94% | 324B | |
+11.07% | 303B | |
+16.96% | 243B | |
+2.25% | 228B | |
+11.15% | 217B | |
+7.59% | 164B | |
-3.65% | 155B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Kala Pharmaceuticals Launches $31 Million Private Placement